137 related articles for article (PubMed ID: 17512704)
21. Short-course cefuroxime axetil therapy in the treatment of acute exacerbations of chronic bronchitis.
Langan C; Clecner B; Cazzola CM; Brambilla C; Holmes CY; Staley H
Int J Clin Pract; 1998; 52(5):289-97. PubMed ID: 9796558
[TBL] [Abstract][Full Text] [Related]
22. Comparative study of levofloxacin in the treatment of children with community-acquired pneumonia.
Bradley JS; Arguedas A; Blumer JL; Sáez-Llorens X; Melkote R; Noel GJ
Pediatr Infect Dis J; 2007 Oct; 26(10):868-78. PubMed ID: 17901791
[TBL] [Abstract][Full Text] [Related]
23. Bronchopulmonary pharmacokinetic and pharmacodynamic profiles of levofloxacin 750 mg once daily in adults undergoing treatment for acute exacerbation of chronic bronchitis.
Nicolau DP; Sutherland C; Winget D; Baughman RP
Pulm Pharmacol Ther; 2012 Feb; 25(1):94-8. PubMed ID: 22210007
[TBL] [Abstract][Full Text] [Related]
24. Levofloxacin versus cefuroxime axetil in the treatment of acute exacerbation of chronic bronchitis: results of a randomized, double-blind study.
Shah PM; Maesen FP; Dolmann A; Vetter N; Fiss E; Wesch R
J Antimicrob Chemother; 1999 Apr; 43(4):529-39. PubMed ID: 10350383
[TBL] [Abstract][Full Text] [Related]
25. An economic evaluation of levofloxacin versus cefuroxime axetil in the outpatient treatment of adults with community-acquired pneumonia.
Rittenhouse BE; Stinnett AA; Dulisse B; Henke CJ; Potter L; Parasuraman B; Martens LL; Williams RR; Kojak C
Am J Manag Care; 2000 Mar; 6(3):381-9. PubMed ID: 10977438
[TBL] [Abstract][Full Text] [Related]
26. [Comparison of the effectiveness of levofloxacin and cefuroxime for the treatment of sinusitis].
Li XP; Qin ZM; Zheng RH; Tan QL; Zhou YY; Zhu L; Yin AF
Lin Chuang Er Bi Yan Hou Ke Za Zhi; 2000 Dec; 14(12):573-5. PubMed ID: 12563960
[TBL] [Abstract][Full Text] [Related]
27. Integrated results of 2 phase 3 studies comparing tigecycline and levofloxacin in community-acquired pneumonia.
Tanaseanu C; Bergallo C; Teglia O; Jasovich A; Oliva ME; Dukart G; Dartois N; Cooper CA; Gandjini H; Mallick R; ;
Diagn Microbiol Infect Dis; 2008 Jul; 61(3):329-38. PubMed ID: 18508226
[TBL] [Abstract][Full Text] [Related]
28. Oral gemifloxacin once daily for 5 days compared with sequential therapy with i.v. ceftriaxone/oral cefuroxime (maximum of 10 days) in the treatment of hospitalized patients with acute exacerbations of chronic bronchitis.
Wilson R; Langan C; Ball P; Bateman K; Pypstra R;
Respir Med; 2003 Mar; 97(3):242-9. PubMed ID: 12645831
[TBL] [Abstract][Full Text] [Related]
29. Short- versus long-duration antimicrobial treatment for exacerbations of chronic bronchitis: a meta-analysis.
Falagas ME; Avgeri SG; Matthaiou DK; Dimopoulos G; Siempos II
J Antimicrob Chemother; 2008 Sep; 62(3):442-50. PubMed ID: 18467303
[TBL] [Abstract][Full Text] [Related]
30. Once-daily, high-dose levofloxacin versus ticarcillin-clavulanate alone or followed by amoxicillin-clavulanate for complicated skin and skin-structure infections: a randomized, open-label trial.
Graham DR; Talan DA; Nichols RL; Lucasti C; Corrado M; Morgan N; Fowler CL
Clin Infect Dis; 2002 Aug; 35(4):381-9. PubMed ID: 12145720
[TBL] [Abstract][Full Text] [Related]
31. Randomized, double-blind study comparing 5- and 7-day regimens of oral levofloxacin in patients with acute exacerbation of chronic bronchitis.
Masterton RG; Burley CJ
Int J Antimicrob Agents; 2001 Dec; 18(6):503-12. PubMed ID: 11738336
[TBL] [Abstract][Full Text] [Related]
32. Moxifloxacin versus levofloxacin for treatment of acute rhinosinusitis: a retrospective database analysis of treatment duration, outcomes, and charges.
Keating KN; Friedman HS; Perfetto EM
Curr Med Res Opin; 2006 Feb; 22(2):327-33. PubMed ID: 16466604
[TBL] [Abstract][Full Text] [Related]
33. Levofloxacin vs. ciprofloxacin plus phenethicillin for the prevention of bacterial infections in patients with haematological malignancies.
Timmers GJ; Simoons-Smit AM; Leidekker ME; Janssen JJ; Vandenbroucke-Grauls CM; Huijgens PC
Clin Microbiol Infect; 2007 May; 13(5):497-503. PubMed ID: 17263835
[TBL] [Abstract][Full Text] [Related]
34. Moxifloxacin monotherapy is effective in hospitalized patients with community-acquired pneumonia: the MOTIV study--a randomized clinical trial.
Torres A; Garau J; Arvis P; Carlet J; Choudhri S; Kureishi A; Le Berre MA; Lode H; Winter J; Read RC;
Clin Infect Dis; 2008 May; 46(10):1499-509. PubMed ID: 18419482
[TBL] [Abstract][Full Text] [Related]
35. Gemifloxacin once daily for 5 days versus 7 days for the treatment of community-acquired pneumonia: a randomized, multicentre, double-blind study.
File TM; Mandell LA; Tillotson G; Kostov K; Georgiev O
J Antimicrob Chemother; 2007 Jul; 60(1):112-20. PubMed ID: 17537866
[TBL] [Abstract][Full Text] [Related]
36. Treatment failure rates and health care utilization and costs among patients with community-acquired pneumonia treated with levofloxacin or macrolides in an outpatient setting: a retrospective claims database analysis.
Ye X; Sikirica V; Schein JR; Grant R; Zarotsky V; Doshi D; Benson CJ; Riedel AA
Clin Ther; 2008 Feb; 30(2):358-71. PubMed ID: 18343274
[TBL] [Abstract][Full Text] [Related]
37. Comparison of the adverse event profiles of levofloxacin 500 mg and 750 mg in clinical trials for the treatment of respiratory infections.
Khashab MM; Xiang J; Kahn JB
Curr Med Res Opin; 2006 Oct; 22(10):1997-2006. PubMed ID: 17022859
[TBL] [Abstract][Full Text] [Related]
38. [Clinicomicrobiological monitoring of patients with exacerbation of chronic bronchitis treated with antibacterial drugs].
Dvoretskiĭ LI; Dubrovskaia NV; Grudinina SA; Filimonova OIu; Iakovlev SV; Sergeeva EV; Sidorenko SV
Ter Arkh; 2006; 78(3):25-35. PubMed ID: 17019954
[TBL] [Abstract][Full Text] [Related]
39. [The effect of fenspiride on the number of exacerbations and the time of first exacerbation in patients with chronic bronchitis].
Pirozyński M; Skucha W; Słomiński M; Chyczewska E; Malinowski J; Nowak D; Bartmińiski W; Pachocki R;
Pol Merkur Lekarski; 2005 Aug; 19(110):139-43. PubMed ID: 16245418
[TBL] [Abstract][Full Text] [Related]
40. [Levofloxacin and macrolides in chronic bronchitis exacerbation: comparative analysis of the treatment efficacy and nonrelapsing periods].
Dvoretskiĭ LI; Dubrovskaia NV; Grudinina SA; Filimonova OIu; Sidorenko SV; Iakovlev SV
Antibiot Khimioter; 2007; 52(7-8):21-31. PubMed ID: 18986021
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
